| Recruiting | 4 | 137 | Europe, Japan, US, RoW | Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant | Novartis Pharmaceuticals, Novartis Pharma AG | Metastatic Breast Cancer | 01/28 | 02/28 | | |
NCT02760030: Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery |
|
|
| Recruiting | 2 | 37 | US | Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Laboratory Biomarker Analysis, Palbociclib, Ibrance, PD-0332991, PD-332991, Questionnaire Administration, Aromatase Inhibitors | Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI) | Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer | 12/23 | 12/24 | | |
THRIVE-65, NCT05535192: TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients |
|
|
| Recruiting | N/A | 270 | US | THRIVE, Health Education Support Program | Dana-Farber Cancer Institute, National Cancer Institute (NCI), Case Western Reserve University, University of Pittsburgh | Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer | 09/26 | 02/27 | | |
